Download Cholesterol-Lowering Therapy: Evaluation of Clinical Trial by Scott M. Grundy PDF

By Scott M. Grundy

Show description

Read or Download Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence PDF

Similar clinical medicine books

The Essential Handbook of Memory Disorders for Clinicians

This concise model of the guide of reminiscence problems is a variety of chapters from the unique quantity which were selected with the busy practitioner in mind.  the fundamental guide presents person clinicians and scholars with these components the editors think about so much correct and necessary on a day by day foundation, as a transportable adjunct to the extra accomplished instruction manual.

Drug Discovery and Evaluation: Methods in Clinical Pharmacology

Drug Discovery and assessment has develop into a progressively more tricky, pricey and time-consuming procedure. The impression of a brand new compound needs to be detected by means of in vitro and in vivo equipment of pharmacology. The task spectrum and the efficiency in comparison to current medicinal drugs need to be made up our minds. As those procedures could be divided up stepwise now we have designed a ebook sequence "Drug Discovery and evaluate" within the type of a suggestion record.

Clinicians Guide to Chronic Headache and Facial Pain

As headache and facial soreness are of the most typical scientific proceedings, it's crucial that clinicians are good outfitted to address those matters. Clinician’s consultant to continual Headache and Facial soreness is designed for all clinicians facing those syndromes in day-by-day practice—whether within the outpatient, emergency, or ambulatory environment.

Additional resources for Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence

Sample text

In the current volume (59). Three trials (60-62) employed intervention on life habits alone; two studies (60,62) used bile acid sequestrants; two others (64,65) employed fibrates alone; and nine trials (66-74) made use of statins alone. Five other trials (75-80) employed combined drug therapy, whereas one study (50) employed the ileal bypass to obtain cholesterol lowering. The details of these trials are presented in other chapters in this volume. A. Angiographic versus Clinical Endpoints In most of the angiographic trials, clinical endpoints were recorded in addition to angiographic trials.

The strength of the POSCH trial grew out of a marked and persistent lowering of LDL cholesterol levels; this study demonstrated clearly that cholesterol lowering reduces major CHD events. B. Unresolved Issues Earlier secondary prevention trials provided mixed results although several of them gave positive results. Generally, the drug trials were more positive than the dietary trials. The two MRC dietary studies (42,43) were taken to be negative; small trends toward benefit of cholesterol lowering did not reach statistical significance.

0 g/day ; and placebo. There were approximately five placebo patients for every two patients on any drug regimen. The primary endpoint was total mortality, and secondary endpoints included various major coronary events. 0 mg/day of D-thyroxine-were discontinued because of trends indicative of adverse effects. The three other regimens-clofibrate, nicotinic acid, and placebo-were continued until the end of the study. Most patients in the latter three groups had at least 5 years of follow-up. The patients treated with clofibrate showed no evidence of benefit, either in total mortality or in cause-specific mortality.

Download PDF sample

Rated 4.47 of 5 – based on 38 votes